KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Gains from Investment Securities (2018 - 2025)

Adaptive Biotechnologies' Gains from Investment Securities history spans 8 years, with the latest figure at $11.1 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 1456.38% year-over-year to $11.1 million; the TTM value through Sep 2025 reached $11.1 million, up 1456.38%, while the annual FY2025 figure was -$578000.0, 104.7% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $11.1 million at Adaptive Biotechnologies, up from $759724.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $156.5 million in Q4 2021 and bottomed at -$114000.0 in Q1 2024.
  • The 5-year median for Gains from Investment Securities is $502667.0 (2023), against an average of $11.1 million.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 1738888.89% in 2021 before it crashed 600.0% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $156.5 million in 2021, then crashed by 100.0% to -$1000.0 in 2022, then plummeted by 600.0% to -$7000.0 in 2023, then surged by 175747.1% to $12.3 million in 2024, then decreased by 10.04% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Gains from Investment Securities are $11.1 million (Q3 2025), $759724.0 (Q2 2025), and -$76000.0 (Q1 2025).